Miltenyi Biomedicine
Jennifer L. Lessor, MPH, is an accomplished executive specializing in market access and health economics within the biopharmaceutical industry. Currently serving as Vice President of Cell Therapy Market Access at Miltenyi Biomedicine since July 2025, Jennifer previously held the position of Head of Market Access and Economics at BioLineRx, where responsibilities included implementing successful market access strategies for the launch of Aphexda. With extensive experience in various roles, including independent consulting for Oncopeptides AB and a Director position at Sanofi Genzyme, Jennifer has established a strong track record in pricing strategy, payer relations, and specialty distribution. Educational qualifications include a Master’s degree in Public Health from The University of Texas Health Science Center at Houston and multiple certifications in project management and health economics.
This person is not in any teams
This person is not in any offices
Miltenyi Biomedicine
2 followers
Miltenyi Biomedicine is a biopharmaceutical company that develops innovative cell and gene therapies. We are committed to bring cancer treatments and regenerative therapies to patients with unmet medical needs worldwide. We work in partnership with physicians and other healthcare providers to expand access to new therapies. Our clinical research program includes: CAR T, CAR NK, our proprietary Adapter CAR™ and induced pluripotent stem cells (iPSC) technologies. For more information, please visit our website at www.miltenyibiomedicine.com.